THE 2022 GENE THERAPY LANDSCAPE REVIEW

Using data from Beacon as of the 16th of January 2023, the following series provides an analysis of the existing Gene Therapy landscape, an overview of what happened in 2022, and a look at what the future might bring.

The four-part analysis is split into:

• The Landscape Overview – An Analysis of the entire drug and trial landscape changes from H2 2022 to now.
• 2022 Highlights – Highlights of the Gene Therapy (GT) collaborations, mergers, and acquisitions of 2022, as well as the regulatory announcements for GT assets.
• Current Trial Landscape – A detailed review of the trial landscape broken down by change of status and phase and a review of assets which entered the clinic in 2022.
• Enrolment Figures + 2023 and Beyond – A comparison of the actual and estimated enrolment figures for the main disease indications of each main gene therapy disease group*

_{*data only shows results from trials which have posted both actual and estimated enrolment figures.}